After randomized phase 3 trials, nivolumab and pembrolizumab, which are monoclonal antibodies against programmed cell death protein 1 (PD-1), have become a standard treatment for patients with advanced NSCLC (3–5). Here, PDCD1 is linked to non-small cell lung carcinoma.